Enveric Biosciences to Present at and Participate in Panel Discussion at Sachs Associates 9th Annual Neuroscience Innovation Forum During "J.P. Morgan Week 2026"
AI Sentiment
Highly Positive
8/10
as of 12-09-2025 11:55am EST
Enveric Biosciences Inc is a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of depression, anxiety, addiction, and other psychiatric disorders. The company's program, EB-003, is a first-in-class approach to the treatment of difficult-to-address mental health disorders designed to promote neuroplasticity without inducing hallucinations in the patient. The company is also developing EB-002, formerly EB-373, a next-generation synthetic prodrug of the active metabolite, psilocin, which is being studied as a treatment for psychiatric disorders.
| Founded: | 1994 | Country: | United States |
| Employees: | N/A | City: | NAPLES |
| Market Cap: | 3.0M | IPO Year: | N/A |
| Target Price: | $120.00 | AVG Volume (30 days): | 33.2K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 1 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -61.29 | EPS Growth: | N/A |
| 52 Week Low/High: | $4.88 - $96.30 | Next Earning Date: | 11-14-2025 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Machine learning model trained on 25+ technical indicators
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
ENVB Breaking Stock News: Dive into ENVB Ticker-Specific Updates for Smart Investing
AI Sentiment
Highly Positive
8/10
See how ENVB stacks up against similar companies in the market
Enhance your trading experience with our free tools
The information presented on this page, "ENVB Enveric Biosciences Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.